Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$104M Sell
5,620,019
-131,319
-2% -$2.62M 1.2% 18
2026
Q1
$108M Buy
5,751,338
+6,200
+0.1% +$116K 1.78% 14
2025
Q4
$89.8M Sell
5,745,138
-2,544
-0% -$37.7K 1.46% 15
2025
Q3
$76.2M Buy
5,747,682
+765,166
+15% +$9.89M 1.16% 14
2025
Q2
$61.9M Buy
4,982,516
+868,359
+21% +$10.9M 0.92% 14
2025
Q1
$62.6M Buy
4,114,157
+823,115
+25% +$12.3M 0.99% 13
2024
Q4
$48M Buy
3,291,042
+1,255,666
+62% +$19.6M 0.71% 16
2024
Q3
$32.5M Buy
2,035,376
+236,400
+13% +$4.2M 0.38% 16
2024
Q2
$34.2M Hold
1,798,976
0.45% 17
2024
Q1
$35.1M Buy
1,798,976
+208,576
+13% +$3.88M 0.32% 20
2023
Q4
$32.3M Buy
1,590,400
+28,500
+2% +$560K 0.34% 19
2023
Q3
$32.6M Buy
+1,561,900
New +$31M 0.42% 20

Other funds holding NOV

Greenhaven Associates's NOV Position: Q2 2026 in Review

Greenhaven Associates reduced its NOV (NOV) stake by 2.3% in Q2 2026, selling an estimated $2.62M and leaving 5,620,019 shares worth $104M. The position accounts for 1.2% of the portfolio, ranked #18.

Greenhaven Associates first reported a position in NOV in Q3 2023 and has held it in 12 quarters since. The position peaked at $108M in Q1 2026. 197 funds tracked by Wall St. Rank hold NOV as of Q2 2026.

  • Greenhaven Associates held 5,620,019 shares of NOV worth $104M as of Q2 2026.
  • Greenhaven Associates sold 131,319 NOV shares in Q2 2026, an estimated $2.62M.
  • NOV made up 1.2% of Greenhaven Associates's portfolio in Q2 2026, its #18 holding.
  • Greenhaven Associates first reported a position in NOV in Q3 2023 and has held it in 12 quarters since.
  • Greenhaven Associates's NOV position peaked at $108M in Q1 2026.
  • 197 funds tracked by Wall St. Rank held NOV as of Q2 2026.

Based on Greenhaven Associates's 13F filing for Q2 2026, filed 28 Jul 2026.